JP2019515894A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515894A5
JP2019515894A5 JP2018552049A JP2018552049A JP2019515894A5 JP 2019515894 A5 JP2019515894 A5 JP 2019515894A5 JP 2018552049 A JP2018552049 A JP 2018552049A JP 2018552049 A JP2018552049 A JP 2018552049A JP 2019515894 A5 JP2019515894 A5 JP 2019515894A5
Authority
JP
Japan
Prior art keywords
eif3
poly
spinocerebellar ataxia
protein
ran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018552049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515894A (ja
JP7509394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/026020 external-priority patent/WO2017176813A1/en
Publication of JP2019515894A publication Critical patent/JP2019515894A/ja
Publication of JP2019515894A5 publication Critical patent/JP2019515894A5/ja
Priority to JP2022047328A priority Critical patent/JP7586506B2/ja
Application granted granted Critical
Publication of JP7509394B2 publication Critical patent/JP7509394B2/ja
Priority to JP2024190590A priority patent/JP2025037864A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018552049A 2016-04-04 2017-04-04 反復関連非atg(ran)翻訳を調節するためのeif3の操作 Active JP7509394B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022047328A JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非atg(ran)翻訳を調節するためのeif3の操作
JP2024190590A JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非atg(ran)翻訳を調節するためのeif3の操作

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318200P 2016-04-04 2016-04-04
US62/318,200 2016-04-04
PCT/US2017/026020 WO2017176813A1 (en) 2016-04-04 2017-04-04 Manipulation of eif3 to modulate repeat associated non-atg (ran) translation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022047328A Division JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非atg(ran)翻訳を調節するためのeif3の操作

Publications (3)

Publication Number Publication Date
JP2019515894A JP2019515894A (ja) 2019-06-13
JP2019515894A5 true JP2019515894A5 (https=) 2020-05-14
JP7509394B2 JP7509394B2 (ja) 2024-07-02

Family

ID=60001473

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552049A Active JP7509394B2 (ja) 2016-04-04 2017-04-04 反復関連非atg(ran)翻訳を調節するためのeif3の操作
JP2022047328A Active JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非atg(ran)翻訳を調節するためのeif3の操作
JP2024190590A Pending JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非atg(ran)翻訳を調節するためのeif3の操作

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022047328A Active JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非atg(ran)翻訳を調節するためのeif3の操作
JP2024190590A Pending JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非atg(ran)翻訳を調節するためのeif3の操作

Country Status (6)

Country Link
US (3) US10940161B2 (https=)
EP (1) EP3440100A4 (https=)
JP (3) JP7509394B2 (https=)
AU (2) AU2017246643B2 (https=)
CA (1) CA3019847A1 (https=)
WO (1) WO2017176813A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
CN109504684B (zh) * 2018-12-20 2021-07-27 山西大学 Ran基因及其dsRNA在害虫防治中的应用
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US20230018989A1 (en) * 2019-07-03 2023-01-19 Children's Medical Center Corporation Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis
EP3994159A4 (en) * 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
EP4041756A4 (en) * 2019-10-10 2023-11-01 University Of Florida Research Foundation, Incorporated RAN PROTEINS AS BIOMARKERS IN CAG/CTG EXPANSION DISORDERS
KR102272985B1 (ko) * 2019-11-20 2021-07-02 충남대학교산학협력단 Eif3b(Eukaryotic translation initiation factor 3 subunit B)를 표적으로 하는 항진균제의 스크리닝 방법

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
ATE247129T1 (de) 1995-04-11 2003-08-15 Merck & Co Inc Biologisches verfahren zur herstellung von verbindungen auf der basis der dipeptiden
CA2283379A1 (en) 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
EP1000084A4 (en) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 HUMAN SECRETED PROTEINS
US6362007B1 (en) 1997-08-29 2002-03-26 Innogenetics N.V. Methylated, SMD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
JP2004518437A (ja) 2000-10-25 2004-06-24 ディアデクサス インコーポレーテッド 肺特異的遺伝子およびタンパク質に関する組成物および方法
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7393642B2 (en) 2003-07-17 2008-07-01 Chicago Community Foundation Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20090075900A1 (en) 2004-04-08 2009-03-19 Sadakazu Therapeutic agent for motor neuron disease
WO2006034278A2 (en) 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
EP1844148A2 (en) 2005-01-31 2007-10-17 University of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
WO2006133194A2 (en) * 2005-06-06 2006-12-14 Vgx Pharmaceuticals, Inc Methods for treating viral infection with oral or injectible drug solution
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
PL2082225T3 (pl) 2006-09-20 2014-06-30 Univ Belfast Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20090148866A1 (en) 2007-05-18 2009-06-11 Abbott Laboratories Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase
EP2164865A2 (en) 2007-06-13 2010-03-24 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
US20090143418A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) * 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
BRPI0923761B1 (pt) 2008-12-30 2019-08-13 3M Innovative Properties Co aerossol adesivo e névoa de aerossol
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2757354A1 (en) * 2009-04-02 2010-10-07 Laura P.W. Ranum Nucleotide repeat expansion-associated polypeptides and uses thereof
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CA2762351A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
WO2011028912A2 (en) 2009-09-03 2011-03-10 University Of Tennessee Research Foundation A biomarker for neurodegeneration in neurological disease
KR101133243B1 (ko) 2009-10-29 2012-04-06 국립암센터 암의 진단 및 치료를 위한 eIF3m의 용도
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9896729B2 (en) 2011-08-31 2018-02-20 The University Of Manchester Method for diagnosing a neurodegenerative disease
US9587014B2 (en) 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014114660A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) 2013-01-24 2016-08-10 Mayo Foundation METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア eIF2α経路の調節因子
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
CA2990161A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP6508996B2 (ja) 2015-03-24 2019-05-08 東ソー株式会社 β−ANPによる心不全の検出方法
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
CN109715144A (zh) 2016-08-18 2019-05-03 奥维德医疗公司 使用双胍类治疗发育障碍的方法
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP3962518A1 (en) 2019-05-02 2022-03-09 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Immunogen for preventing or treating familial frontotemporal dementia (ftd) and/or amyotrophic lateral sclerosis (als)
EP3994159A4 (en) 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
WO2021061537A1 (en) 2019-09-23 2021-04-01 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
EP4041756A4 (en) 2019-10-10 2023-11-01 University Of Florida Research Foundation, Incorporated RAN PROTEINS AS BIOMARKERS IN CAG/CTG EXPANSION DISORDERS
WO2021231887A1 (en) 2020-05-15 2021-11-18 University Of Florida Research Foundation, Incorporated Compositions and methods of detection of pre-symptomatic als
EP4440560A1 (en) 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Similar Documents

Publication Publication Date Title
JP2019515894A5 (https=)
AU2022252755B2 (en) Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
Bhatti et al. Emerging role of non‐coding RNA in health and disease
Barata et al. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions
Gait et al. Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
CA2924535C (en) Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations
Falzarano et al. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy
JP2024081635A5 (https=)
Lindley et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies
JP2018521014A5 (https=)
JP2006515864A5 (https=)
JP2011520444A5 (https=)
RU2015155332A (ru) Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение
Hu et al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs
Hammond et al. Mesyl phosphoramidate oligonucleotides as potential splice-switching agents: impact of backbone structure on activity and intracellular localization
Ghaffari et al. Delivery of antisense peptide nucleic acid by gold nanoparticles for the inhibition of virus replication
Buthelezi et al. Antisense therapy for infectious diseases
Esposito et al. Aptamer-MiRNA conjugates for cancer cell-targeted delivery
Delcroix et al. Cell-penetrating peptides for antiviral drug development
Liu et al. Delivery of miRNA‐29b using R9‐LK15, a novel cell‐penetrating peptide, promotes osteogenic differentiation of bone mesenchymal stem cells
Batra et al. Molecular engineering of functional SiRNA agents
Fabbri et al. miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs
Zhang et al. Conditional antisense oligonucleotides triggered by miRNA
Kiaie et al. Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells
Wheeler Silencing Sexually Transmitted Infections: Topical siRNA‐Based Interventions for the Prevention of HIV and HSV